Medical Ikkou Group Co., Ltd. (3353) AI Stock Analysis

• Market Cap: ¥8.38B
• Dividend Yield: 0.41%
• Average Volume (3M): 1.93K
• Price to Earnings (P/E): 8.1
• Beta (1Y): 0.45
• Revenue Growth: 21.28%
• EPS Growth: 8.92%
• Country: JP
• Employees: 1,431
• Sector: Industrials
• Sector Strength: 83
• Industry: Conglomerates
• EPS (TTM): 35.57
• Shares Outstanding: 3,770,000
• 10 Day Avg. Volume: 1,980
• 30 Day Avg. Volume: 1,926
• PEG Ratio: -1.18
• Price to Book (P/B): 0.81
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 10.13
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 84 Outperform
• Price Target: ―

Medical Ikkou Group Co., Ltd. exhibits a robust financial performance with strong revenue growth and operational efficiency, though cash flow management poses challenges. The technical analysis shows positive momentum but potential overbought conditions. Valuation metrics indicate potential undervaluation with a low P/E ratio and a solid dividend yield, making it an attractive investment opportunity.

Medical Ikkou Group Co., Ltd. Business Overview & Revenue Model

Company Description

Medical Ikkou Group Co., Ltd. (3353) is a Japan-based company primarily engaged in the pharmaceutical and healthcare sectors. The company operates a chain of pharmacies, offering prescription medications, over-the-counter drugs, and health-related products. Additionally, it provides home delivery services for pharmaceuticals and engages in the sale of medical equipment. The group aims to enhance community health through its comprehensive healthcare solutions and expert pharmaceutical services.

How the Company Makes Money

Medical Ikkou Group Co., Ltd. generates revenue primarily through its network of pharmacy stores, which sell prescription medications and over-the-counter drugs to individuals. Another significant revenue stream comes from the sale of health-related products, including nutritional supplements and wellness goods. The company also earns income by offering home delivery services for pharmaceuticals, providing convenience to customers who need medications delivered to their homes. Additionally, Medical Ikkou Group sells medical equipment to healthcare institutions and individuals, further diversifying its revenue streams. Partnerships with pharmaceutical manufacturers and healthcare providers play a crucial role in expanding its product offerings and maintaining competitive pricing, thereby contributing to its overall earnings.

Medical Ikkou Group Co., Ltd. Financial Statement Overview

Summary

Medical Ikkou Group Co., Ltd. demonstrates strong revenue growth and operational efficiency, but faces challenges in net profitability and cash flow management. The balance sheet reflects stability with a healthy equity ratio and manageable debt levels. While the income statement shows a positive growth trajectory, cash flow constraints could impact future financial flexibility.

Income Statement

Medical Ikkou Group Co., Ltd. has shown strong revenue growth with a 21.3% increase from 2024 to 2025. The gross profit margin has improved to 11.6% in 2025 from 11.4% in 2024, indicating better cost management. The EBIT margin also improved to 3.5% in 2025 from 3.9% in 2024, showcasing operational efficiency. However, the net profit margin remained stable at around 2.3%, suggesting room for improvement in net profitability.

Balance Sheet

The company maintains a healthy equity ratio of 41.2% in 2025, reflecting strong solvency. The debt-to-equity ratio decreased to 0.71 in 2025 from 0.72 in 2024, showing effective debt management. ROE was stable at 8.0% in 2025, indicating consistent return on shareholders' equity. However, the total debt level remains significant, which could pose a risk if not managed properly.

Cash Flow

Operating cash flow decreased significantly to ¥1.2 billion in 2025 from ¥4.3 billion in 2024, negatively impacting free cash flow, which dropped by 94.9%. The free cash flow to net income ratio declined, signaling potential cash flow issues relative to earnings. However, the company generated positive free cash flow, indicating some level of operational efficiency.

Breakdown
TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement		Total Revenue
46.22B	48.39B	39.90B	33.90B	33.60B	31.60B
	Gross Profit
5.46B	5.61B	4.55B	3.18B	3.61B	3.20B
	EBIT
1.68B	1.69B	1.56B	935.17M	1.28B	1.03B
	EBITDA
2.68B	2.73B	2.50B	2.21B	2.41B	2.33B
	Net Income Common Stockholders
1.23B	1.13B	1.04B	759.60M	852.33M	834.99M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
8.76B	6.77B	7.70B	6.44B	7.99B	7.00B
	Total Assets
35.44B	34.23B	31.66B	27.51B	29.09B	28.55B
	Total Debt
10.26B	10.02B	9.58B	9.12B	11.31B	11.85B
	Net Debt
1.50B	3.25B	1.88B	2.67B	3.32B	4.84B
	Total Liabilities
20.85B	19.52B	17.82B	14.90B	17.17B	18.07B
	Stockholders Equity
13.96B	14.10B	13.24B	12.05B	11.38B	10.48B
Cash Flow		Free Cash Flow
0.00	201.34M	3.95B	960.14M	798.00M	1.33B
	Operating Cash Flow
0.00	1.20B	4.28B	1.31B	1.14B	1.82B
	Investing Cash Flow
0.00	-1.13B	-3.22B	-477.52M	-215.52M	-1.18B
	Financing Cash Flow
0.00	-1.03B	277.76M	-2.37B	64.74M	590.88M

Medical Ikkou Group Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2441.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3353, the sentiment is Positive. The current price of 2441 is above the 20-day moving average (MA) of 2407.65, above the 50-day MA of 2349.16, and above the 200-day MA of 2215.02, indicating a bullish trend. The MACD of 31.45 indicates Positive momentum. The RSI at 61.87 is Neutral, neither overbought nor oversold. The STOCH value of 47.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3353.

Medical Ikkou Group Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3353	84 Outperform	¥8.38B	8.05		0.41%	21.28%	8.92%
6554	78 Outperform	¥10.34B	12.24		2.62%	19.85%	78.11%
7795	73 Outperform	¥7.51B	10.51		4.65%	0.83%	-21.02%
7670	72 Outperform	¥9.12B	5.14		3.91%	-2.30%	16.50%
7490	70 Outperform	¥6.77B	11.00		3.15%	0.78%	106.93%
7066	69 Neutral	¥6.37B	11.82		2.50%	7.60%	37.77%
Sector *	66 Neutral	$4.46B	12.15	5.40%	4.71%	4.16%	-11.97%